BIOAGE LABS INC
BIOANASDAQTrading Snapshot
- Day Range
- $10.61 – $10.87
- 52-Week Range
- $4.25 – $25.96
- Volume
- $3.26B
- Avg Volume
- $3.31B
- Shares Outstanding
- 44.5M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 50.9x
- EPS (TTM)
- $-2.40
- Dividend Yield
- —
Why Investors Own BIOA
- ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOAGE LABS INC
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top stock movements in today's session.
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
Gapping stocks in Friday's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.